The importance of 15-lipoxygenase inhibitors in cancer treatment

Ala Orafaie1, Maryam Moghaddam Matin1,2, Hamid Sadeghian3,4

  • 1Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.

Insights

15-Lipoxygenase (15-LOX) inhibitors show promise as novel cancer therapeutics. This review explores their anticancer activities, suggesting potential as future chemotherapy agents.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Cancer-targeted therapy, particularly small molecule inhibitors, is a growing field.
  • 15-Lipoxygenase (15-LOX) produces metabolites linked to cancer progression.
  • 15-LOX-1 specifically plays a role in the development of certain cancers.

Purpose of the Study:

  • To review existing literature on 15-Lipoxygenase (15-LOX) inhibitors.
  • To focus on the anticancer activities of these inhibitors.
  • To explore their potential as future cancer therapeutics.

Main Methods:

  • Literature review of publications on 15-LOX inhibitors.
  • Analysis of studies reporting in vitro anticancer activities.
  • Evaluation of studies reporting in vivo anticancer activities.

Main Results:

  • Numerous 15-LOX inhibitors have been identified.
  • Separate studies demonstrate anticancer effects for many reported inhibitors.
  • Evidence suggests 15-LOX inhibition impacts cancer cell proliferation.

Conclusions:

  • 15-LOX inhibitors represent a promising area for novel cancer therapeutics.
  • These inhibitors may serve as effective chemotherapy agents in the future.
  • Further research into the mechanisms of antiproliferative effects is warranted.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
618
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Other Nuclides: 31P, 19F, 15N NMR01:16

Other Nuclides: 31P, 19F, 15N NMR

Many organic, inorganic, and biological molecules contain spin-half nuclei such as nitrogen-15, fluorine-19, and phosphorus-31. As a result, NMR studies of these nuclei have found extensive applications in chemical and biological research.
While fluorine-19 and phosphorous-31 have high natural abundances (100%) and positive gyromagnetic ratios, nitrogen-15 has a low natural abundance and a negative gyromagnetic ratio. However, nitrogen-15 is still preferred over nitrogen-14 (which has a...
796
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
551
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
687